Login to Your Account



Receptos basks in 'RADIANCE' of full phase II dataset for MS drug

By Marie Powers
Staff Writer

Friday, September 12, 2014
Shares of Receptos Inc. (NASDAQ:RCPT) spiked 20 percent last week, hitting a 52-week high of $61.13 on Thursday, after the abstract was posted for Saturday's late-breaker podium presentation at MS Boston 2014 of the complete dataset from the phase II portion of the company's phase II/III RADIANCE trial of RPC1063 in relapsing multiple sclerosis (RMS).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription